These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32532777)

  • 1. Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry.
    Phillips R; Cornelius V
    BMJ Open; 2020 Jun; 10(6):e036875. PubMed ID: 32532777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis and reporting of adverse events in randomised controlled trials: a review.
    Phillips R; Hazell L; Sauzet O; Cornelius V
    BMJ Open; 2019 Mar; 9(2):e024537. PubMed ID: 30826796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to multiplicity in publicly funded pragmatic randomised controlled trials: a survey of clinical trials units and a rapid review of published trials.
    Pike K; Reeves BC; Rogers CA
    BMC Med Res Methodol; 2022 Feb; 22(1):39. PubMed ID: 35125091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.
    Cook JA; Hislop J; Adewuyi TE; Harrild K; Altman DG; Ramsay CR; Fraser C; Buckley B; Fayers P; Harvey I; Briggs AH; Norrie JD; Fergusson D; Ford I; Vale LD
    Health Technol Assess; 2014 May; 18(28):v-vi, 1-175. PubMed ID: 24806703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinding of study statisticians in clinical trials: a qualitative study in UK clinical trials units.
    Iflaifel M; Partlett C; Bell J; Cook A; Gamble C; Julious S; Juszczak E; Linsell L; Montgomery A; Sprange K
    Trials; 2022 Jun; 23(1):535. PubMed ID: 35761345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliciting adverse effects data from participants in clinical trials.
    Allen EN; Chandler CI; Mandimika N; Leisegang C; Barnes K
    Cochrane Database Syst Rev; 2018 Jan; 1(1):MR000039. PubMed ID: 29372930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations.
    Smith SM; Wang AT; Katz NP; McDermott MP; Burke LB; Coplan P; Gilron I; Hertz SH; Lin AH; Rappaport BA; Rowbotham MC; Sampaio C; Sweeney M; Turk DC; Dworkin RH
    Pain; 2013 Jul; 154(7):997-1008. PubMed ID: 23602344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy.
    Phillips R; Sauzet O; Cornelius V
    BMC Med Res Methodol; 2020 Nov; 20(1):288. PubMed ID: 33256641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study.
    Blatch-Jones A; Nuttall J; Bull A; Worswick L; Mullee M; Peveler R; Falk S; Tape N; Hinks J; Lane AJ; Wyatt JC; Griffiths G
    Trials; 2020 Apr; 21(1):304. PubMed ID: 32245506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying research priorities for effective retention strategies in clinical trials.
    Kearney A; Daykin A; Shaw ARG; Lane AJ; Blazeby JM; Clarke M; Williamson P; Gamble C
    Trials; 2017 Aug; 18(1):406. PubMed ID: 28859674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials.
    Dimairo M; Julious SA; Todd S; Nicholl JP; Boote J
    Trials; 2015 Dec; 16():585. PubMed ID: 26700741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best practice guidance for the use of strategies to improve retention in randomized trials developed from two consensus workshops.
    Brueton V; Stenning SP; Stevenson F; Tierney J; Rait G
    J Clin Epidemiol; 2017 Aug; 88():122-132. PubMed ID: 28546093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
    Cornelius V; Cro S; Phillips R
    Trials; 2020 Dec; 21(1):1028. PubMed ID: 33353566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recording harms in randomised controlled trials of behaviour change interventions: a qualitative study of UK clinical trials units and NIHR trial investigators.
    Papaioannou D; Sprange K; Hamer-Kiwacz S; Mooney C; Moody G; Cooper C
    Trials; 2024 Mar; 25(1):163. PubMed ID: 38438935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing guidance for a risk-proportionate approach to blinding statisticians within clinical trials: a mixed methods study.
    Iflaifel M; Sprange K; Bell J; Cook A; Gamble C; Julious SA; Juszczak E; Linsell L; Montgomery A; Partlett C
    Trials; 2023 Jan; 24(1):71. PubMed ID: 36721215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.